Ascletis’ Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
Only social or community posts, or a single source.
What happened
– With first patient dosed in Phase III clinical trial, Ascletis’ strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)’s U.S. registrational program, building on positive Phase III clinical results in China from Ascletis (Kosmo!, 00:10)
The reporting
1 report
Photo: Kosmo! Kosmo!·News·EN·23 Oct, 00:10 MYTAscletis’ Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
– With first patient dosed in Phase III clinical trial, Ascletis’ strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)’s U.S.
Read at Kosmo!
Headlines, short summaries and photos belong to the outlets credited; each report is read on the outlet's own site.
Why it is new
- No engagement data available from these sources; score uses mention signals only
Attention graph
Timeline
- DetectedFirst detected (Kosmo!) source
Where it started
How it spread
- Step 1News outletsKosmo!00:10
Internet reaction
No social or community posts about this yet from the platforms we ingest.
What we know
- Covered by 1 established outlet(s): Kosmo!
What we don’t know
- Independent confirmation is missing; treat specifics as unverified
- Only one source so far
All sources (1)
Attention is measured from these mentions only. Platforms shown: News. We never invent signals for platforms we do not ingest.
Follow for your feed
Follow the topic or the people and places in this story and they shape your For you page. Kept in this browser only.